Medicines

Transforming Ideas Into Treatments

Our passion for patients in need fuels our dedication to fill the therapeutic void with hope for the future. With RNA as the basis of our discovery platform, we are able to bring therapeutic options to patients who otherwise would have limited or no options.

Ionis has discovered and developed five currently marketed medicines for serious diseases, including breakthrough medicines for neurologic and cardiovascular diseases.

WAINUA

For more information about WAINUA and US prescribing information, visit WAINUA.com.

Visit Site

QALSODY

For more information about QALSODY and US prescribing information, visit QALSODY.com.

Visit Site

SPINRAZA

For more information about SPINRAZA and US prescribing information, visit SPINRAZA.com.

Visit Site

Tegsedi

For TEGSEDI prescribing information in the EU, please visit ema.europa.eu/en/medicines/human/EPAR/tegsedi.

Visit Site

Medicine not available in the US.

Waylivra

For WAYLIVRA prescribing information in the EU, please visit ema.europa.eu/en/medicines/human/EPAR/waylivra.

Visit Site

Medicine not available in the US.

View our Clinical Pipeline

See Our Pipeline

We are relentlessly pursuing the innovations of tomorrow with our broad and diverse pipeline of potential first or best-in-class investigational therapies designed to treat a range of diseases. Learn more about our pipeline.

WAINUA
True

For more information about WAINUA™ and U.S. prescribing information, visit WAINUA.com.

False
False
QALSODY
True

For more information about QALSODY® and U.S. prescribing information, visit QALSODY.com.

False
False
SPINRAZA
True

For more information about SPINRAZA® and U.S. prescribing information, visit SPINRAZA.com.

False
False
TEGSEDI
False

For TEGSEDI® prescribing information in the EU, please visit ema.europa.eu/en/medicines/human/EPAR/tegsedi.

False
False
WAYLIVRA
False

For WAYLIVRA® prescribing information in the EU, please visit ema.europa.eu/en/medicines/human/EPAR/waylivra.

False
False